TENORMIN Drug Patent Profile

When do Tenormin patents expire, and what generic alternatives are available?

Tenormin is a drug marketed by Astrazeneca and Twi Pharms and is included in two NDAs.

The generic ingredient in TENORMIN is atenolol. There are thirty-four drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the atenolol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tenormin

A generic version of TENORMIN was approved as atenolol by TWI PHARMS on July 15^th, 1988.

Summary for TENORMIN

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	163
Clinical Trials:	16
Patent Applications:	5,116
Drug Prices:	Drug price information for TENORMIN
What excipients (inactive ingredients) are in TENORMIN?	TENORMIN excipients list
DailyMed Link:	TENORMIN at DailyMed

See drug prices for TENORMIN

Recent Clinical Trials for TENORMIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Tennessee Medical Center	Early Phase 1
High Risk Obstetrical Consultants	Early Phase 1
University of Tennessee Graduate School of Medicine	Early Phase 1

See all TENORMIN clinical trials

Pharmacology for TENORMIN

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

US Patents and Regulatory Information for TENORMIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	TENORMIN	atenolol	INJECTABLE;INJECTION	019058-001	Sep 13, 1989		DISCN	Yes	No
Twi Pharms	TENORMIN	atenolol	TABLET;ORAL	018240-002	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes
Twi Pharms	TENORMIN	atenolol	TABLET;ORAL	018240-004	Apr 9, 1990	AB	RX	Yes	No

Expired US Patents for TENORMIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Twi Pharms	TENORMIN	atenolol	TABLET;ORAL	018240-001	Approved Prior to Jan 1, 1982	3,934,032
Twi Pharms	TENORMIN	atenolol	TABLET;ORAL	018240-004	Apr 9, 1990	3,836,671
Twi Pharms	TENORMIN	atenolol	TABLET;ORAL	018240-002	Approved Prior to Jan 1, 1982	3,836,671

International Patents for TENORMIN

See the table below for patents covering TENORMIN around the world.

Country	Patent Number	Title	Estimated Expiration
Switzerland	553747	VERFAHREN ZUR HERSTELLUNG VON ALKANOLAMINDERIVATEN.
Yugoslavia	193575
U.S.S.R.	452091

TENORMIN Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Tenormin (Atenolol)

Introduction

Tenormin, known generically as atenolol, is a widely used beta-blocker primarily prescribed for the treatment of hypertension, angina, and certain heart rhythm disorders. This article delves into the market dynamics and financial trajectory of Tenormin, highlighting key drivers, challenges, and future projections.

Market Size and Growth

The global atenolol market, which includes Tenormin, is experiencing significant growth. As of 2023, the market size was valued at USD 11.59 billion and is projected to reach USD 22.97 billion by 2036, growing at a Compound Annual Growth Rate (CAGR) of approximately 5.4% during the forecast period of 2024-2036[1].

Growth Drivers

Several factors are driving the growth of the atenolol market:

Increasing Prevalence of Hypertension

The global prevalence of hypertension is on the rise, with an estimated 1.28 billion people aged 30-79 years suffering from the condition. This is particularly prevalent in low- and middle-income countries, where two-thirds of these individuals reside[1].

Aging Population

The global population of people aged 60 and above is expected to increase significantly, from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050. This demographic shift is crucial because older individuals are more prone to hypertension and other cardiovascular diseases[1].

Lifestyle Factors

Poor lifestyle choices, including poor dietary habits and increased fast food consumption, are contributing to the rising incidence of hypertension and other cardiovascular disorders, thereby driving the demand for antihypertensive drugs like atenolol[1].

Market Segmentation

The atenolol market is segmented based on application and distribution channels.

Application

Atenolol is primarily used for treating hypertension, angina, and arrhythmia. The increasing burden of these conditions globally is a key driver for the market[1].

Distribution Channels

The market is segmented into hospital pharmacies, drug stores, online pharmacies, and others. Hospital pharmacies are expected to garner a significant share, around 49% by 2036, due to the rising patient pool seeking treatment for cardiovascular diseases in hospitals. Online pharmacies are also expected to witness impressive growth due to increasing internet penetration and awareness of online platforms[1].

Regional Market Dynamics

North America

The North American market is projected to hold the largest share, approximately 40% by 2036, driven by the high prevalence of cardiac diseases and hypertension in the region. For instance, in the U.S., 116 million individuals have hypertension, and hypertension-related deaths were significant in 2019[1].

Asia Pacific

The Asia Pacific region is expected to be the second largest market, with a share of about 28% by 2036. The growth here is attributed to the rising burden of hypertension, changing lifestyles, and increasing awareness about hypertension drugs[1].

Europe

In Europe, the market dynamics are influenced by regulatory changes and divestments. For example, AstraZeneca divested the worldwide commercial rights of Tenormin (atenolol) to Atnahs Pharma, which has impacted the market structure in the region[4].

Financial Trajectory

Historical Sales

In 2018, Tenormin and other related hypertension medicines generated annual sales of $132 million in the markets covered by the divestment agreement between AstraZeneca and Atnahs Pharma[4].

Divestment and Financial Implications

AstraZeneca received an upfront payment of $350 million from Atnahs Pharma, with potential future sales-contingent payments of up to $40 million between 2020 and 2022. This divestment was part of AstraZeneca's strategy to focus on core brands and invest in new medicines[4].

Current and Future Projections

Given the growing demand for antihypertensive drugs, the financial trajectory for Tenormin is expected to remain positive. The increasing prevalence of hypertension and the aging population will continue to drive sales. Additionally, the expansion of online pharmacies and improved healthcare infrastructure will further boost the market[1].

Challenges

Despite the positive growth projections, there are several challenges that the atenolol market faces:

Generic Competition

The availability of generic versions of atenolol can reduce the market share of branded products like Tenormin.

Regulatory Changes

Changes in regulatory environments and healthcare policies can impact the market dynamics and sales of atenolol.

Lifestyle and Dietary Changes

While poor lifestyle choices drive the demand for atenolol, public health initiatives aimed at reducing hypertension through lifestyle changes could potentially reduce the long-term demand for the drug.

Key Takeaways

• The global atenolol market is expected to grow significantly, driven by the increasing prevalence of hypertension and the aging population.
• North America and the Asia Pacific region are key markets for atenolol.
• Hospital pharmacies and online pharmacies are crucial distribution channels.
• AstraZeneca's divestment of Tenormin's commercial rights to Atnahs Pharma has reshaped the market landscape.
• Despite challenges, the financial trajectory for Tenormin remains positive due to ongoing demand for antihypertensive medications.

FAQs

What is the current market size of the atenolol market?

The atenolol market size was valued at USD 11.59 billion in 2023[1].

What is the projected growth rate of the atenolol market?

The atenolol market is expected to grow at a CAGR of approximately 5.4% from 2024 to 2036[1].

Which region holds the largest share of the atenolol market?

North America is projected to hold the largest share, approximately 40% by 2036[1].

Why did AstraZeneca divest the rights to Tenormin?

AstraZeneca divested the rights to Tenormin as part of its strategy to focus on core brands and invest in new medicines[4].

What are the primary distribution channels for atenolol?

Hospital pharmacies and online pharmacies are the primary distribution channels, with hospital pharmacies expected to hold around 49% of the market share by 2036[1].

Sources

1. Research Nester: Atenolol Market Size & Share, Growth Forecasts 2024-2036.
2. AstraZeneca: Full year and Q4 2021 results - AstraZeneca.
3. Annual Reports: AstraZeneca Annual Report 2006.
4. AstraZeneca: AstraZeneca divests rights to established hypertension medicines.